Bulletin Board
Bulletin Board
Clock Ticking on Some Telehealth Prescribing?
The COVID-inspired flexibility to prescribe some medicines via telehealth will soon expire – and it is not clear whether the practice will be extended. While there is general support for telehealth prescribing, policymakers appear to be divided over whether to permit continued use of telehealth to prescribe Schedule 2 drugs such as Adderall. The next step in clearing the path to extending the flexibility was supposed to be a proposed regulation from the Drug Enforcement Agency. The DEA has submitted a draft to the Office of Management and Budget for [...]
Federal Health Policy Update for September 5
The following is the latest health policy news from the federal government for August 31 – September 5. Some of the language used below is taken directly from government documents. Centers for Medicare & Medicaid Services CMS has posted a bulletin outlining changes coming in the FY 2025 inpatient and long-term-care hospital prospective payment system. Find that bulletin here. The changes it presents take effect on October 1. CMS has posted a bulletin about new waived laboratory tests that outlines Clinical Laboratory Improvement Amendments (CLIA) requirements, new CLIA-waived tests approved [...]
Telehealth Gains in Jeopardy?
The ability of doctors to use telehealth to prescribe medicines like buprenorphine for patients with opioid use disorder may be in jeopardy. While COVID-19 inspired an expanded use for caring for patients using telehealth, the regulatory flexibility that made remote prescribing possible expires at the end of 2024 and the federal Drug Enforcement Agency appears reluctant to call for its extension without modification. In particular, an unreleased DEA proposal reportedly would limit individual physicians to issuing no more than half of their prescriptions virtually. Some people think this would detract [...]
Federal Health Policy Update for August 30
The following is the latest health policy news from the federal government for August 23-30. Some of the language used below is taken directly from government documents. 340B Johnson & Johnson, the pharmaceutical, biotechnology, and medical technologies company, told health care providers this week that it would shift from the long-time 340B upfront discount approach to a rebate model for two of its drugs and that eligible 340B hospitals and other providers will need to purchase the prescription drugs Stelara and Xarelto at list price and then, after dispensing them [...]
States Stepping Into Prior Authorization Void
While federal lawmakers continue to weigh how to address the problem of prior authorization requirements that cause delays in the delivery of health care, many state governments are acting more decisively by implementing prior authorization reforms of their own. This year, 10 states have enacted 18 laws designed to facilitate prior authorization of medical services and in 2023, nine states and the District of Columbia did so. In all, 23 states have introduced prior authorization reforms in recent years. At the same time, some health insurers have reduced the number [...]